Abstract
Background: The polymer/carrier-free Biolimus A9 drug-coated BioFreedom® stent (Biosensors, Europe) has been shown to be superior to bare-metal stent in patients at high risk for bleeding. The sirolimus-eluting endothelial progenitor cell capture Combo® stent (OrbusNeich Medical, Florida) has also been shown to be safe with 1 month DAPT. Both stents are useful in patients with high bleeding risk requiring short duration of DAPT and unknown compliance to DAPT. However, the efficacy of Combo® stent compared to BioFreedom® stent is unknown.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
